Milo Therapeutics   Report issue

For profit Phase 2
Founded: Columbus OH United States (2012)
Status: Defunct (2020)

Organization Overview

First Clinical Trial
2015
NCT02354781
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

raav1.cmv.hufollistatin344 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Muscular Dystrophies (Phase 2)

Muscular Dystrophy, Duchenne (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1